Medline Inc. (MDLN) stock analysis
In our weekly check, Medline Inc. is graded B (A to F). Of 20 checks on debt, profit, cash flow and trend: 14 pass, warnings: 4, red flags: 2.
About Medline Inc.
Medline Inc. is a Healthcare company (Medical - Instruments & Supplies) based in the United States, listed on NASDAQ as MDLN.
What our checks show for MDLN
Red flags
- The net margin is only 1.8%: little room if costs rise.
- Return on capital (ROCE) is only 4.7%.
Warning signs
- Net debt is 3.9x a year of EBITDA (debt/equity 1.07). That limits room in a downturn and raises refinancing risk.
- Operating profit covers interest only 2.6 times: a weak year could make the payments hard.
- Free cash flow is only 4.2% of revenue.
- The price swings a lot: 47.5% annual volatility. Expect large ups and downs.
Strengths
- Operating cash flow is 3.09x net profit: the profit arrives as real cash.
- Analysts expect earnings per share to grow about 53.6% a year over the next years.
- Earnings per share grew 176% a year over the last 3 years.
- The dividend takes 17% of profit: there is a cushion.
- A large company: market value $34.68 billion.
- Beta -0.39: the stock usually moves less than the market.
Similar companies
RMD · WST · BDX · SOLV · BAX · COO
Questions
What grade does Medline Inc. (MDLN) have?
In our weekly check, Medline Inc. is graded B (A to F). Of 20 checks on debt, profit, cash flow and trend: 14 pass, warnings: 4, red flags: 2. The grade is a risk check, not a buy or sell recommendation.
What are the main risks of MDLN stock?
This week's biggest flags for Medline Inc.: Thin margins, Low return on capital, High debt. In total 6 of 20 checks show a warning or a red flag.
What does Medline Inc. do?
Medline Inc. is a Healthcare company (Medical - Instruments & Supplies) based in the United States, listed on NASDAQ as MDLN.
The grade is a risk check, not a price forecast, and not investment advice. In our 10-year test (S&P 500, 2016-2026), stocks we graded A or B fell more than 30% 2-3 times less often than D or F, without a lower average return.
Updated 2026-11-14
Open the full analysis